Providing Consultative DMPK Solutions Bridging Drug Discovery and Development
21 Nov 2013

XenoTech and XenoGesis work together to facilitate outsourced drug metabolism and pharmacokinetics (DMPK) studies from early stage drug discovery through development and beyond. The partnership was developed to help mitigate the risk and cost associated with clinical failure. Efficacy and safety are now the leading causes of attrition and are linked to drug exposure in target and off-target tissues. While pharmacokinetics is no longer the leading cause of failure, a drug’s exposure is driven by its pharmacokinetic properties and ultimately remains critical for successful pharmacodynamics and safety. This webinar will showcase the consultative basis of the DMPK CRO alliance and highlight the capabilities with real-life examples of our unique combination of expertise.

Xenotech LLC



Show    per page
1 of 9 Page     1 2 3  ... Next 
Characterization of Glycoproteins: 25 Years of HPAEC-PAD Analysis28 Oct 2014Read
Validation of the TruSight One Sequencing Panel for Clinical Research16 Oct 2014Read
Ion Mobility Derived Collision Cross Sections to Support Metabolomics and Lipidomics15 Oct 2014Read
Non-targeted and Targeted Analysis of Anionic Metabolites Using Ion Chromatography and High Resolution Accurate Mass Spectrometry1 Oct 2014Read
A new approach to improving early characterization of therapeutic formulations - Viscosizer 2005 Sep 2014Read
An introduction to capillary rheometry - Evaluating material properties under process relevant conditions5 Sep 2014Read
Speed your way though your protein formulation screening by automating your measurements5 Sep 2014Read
Novel analytical technologies for product deformulation - Part 25 Sep 2014Read
Water treatment - Optimize coagulant dosing using zeta potential5 Sep 2014Read
Applications of rheology in the waxes, creams and emulsions arena5 Sep 2014Read